Natto: Rudi De Man Named VP Sales & Business Development of NattoPharma ASA

OSLO, NORWAY – (May 20, 2015)  Rudi De Man has been appointed Vice President of
Sales and Business Development of NattoPharma ASA, responsible for Europe and
Asia.
“NattoPharma ASA recognizes that the European and Asian markets pose a huge
growth potential for our science-based MenaQ7 Vitamin K2 as MK-7,” says Frode M.
Bohan, Chairman of the Board of NattoPharma ASA, Høvik, Norway. “This
opportunity requires a dedicated hand, which is why we have added Rudi De Man to
our global management team. He brings a deep understanding of these markets from
his nutraceutical and food ingredients background, reinforcing NattoPharma’s
great expectations for the future.”

Prior to joining NattoPharma, De Man held sales leadership and business
development roles where he was directly responsible for driving record growth in
the FMC Health and Nutrition division, a $900M group within FMC Corporation, a
$4 billion diversified chemical company. During his 19-year tenure at FMC, De
Man served in a variety of sales roles with increasing responsibility, acquiring
international sales experience and an extensive knowledge of the Food
Ingredients and Pharmaceutical & Nutraceutical business. His most recent
position was Sales Director Europe, Middle East, Africa, and Eastern Europe for
Food Stabilizers and Colors, where he was responsible for managing the Food and
Personal Care business. Further, with a degree in Biochemistry and as a Chemical
Engineer, De Man played an integral role at a leading European starch producer
developing a new range of more performant drilling starches, while setting up a
network of distributors in Asia.

“De Man has achieved proven successes maintaining relationships and acquiring
new business through a thorough understanding of his company’s technologies, and
how they could benefit his customers,” says Hogne Vik, NattoPharma CEO. "With an
extensive knowledge of the nutraceutical and pharmaceutical industries, we are
confident he will be an engaging member of our global management team, guiding
our current and potential partners on a mutually profitable path to create
innovative products that take full advantage of our clinically validated MenaQ7
Vitamin K2 as MK-7.”

Reporting to NattoPharma COO Daniel H. Rosenbaum, De Man will be responsible for
driving sales in Europe and Asia, while growing awareness of MenaQ7®. He will
provide technical expertise to regional partners and key accounts, identifying
and developing opportunities to leverage existing proprietary MenaQ7 Vitamin K2
science and technology, and directly contributing to the company’s global
strategy and growth intiatives.

# # #

About MenaQ7®

MenaQ7® provides natural vitamin K2 as a manufactured fermentation extract. This
process generates a highly pure and bio-available form of vitamin K2,
menaquinone-7 (MK-7). MenaQ7 is the purest vitamin K2 on the market. MenaQ7 is
the only vitamin K2 with proven positive clinical health effects on bones and
the cardiovascular system. MenaQ7 vitamin K2 is the only vitamin K2 supported by
several granted patents on cardiovascular health worldwide.

About NattoPharma

As a biotechnology and nutraceutical company, NattoPharma is the worldwide
pioneer and innovator for developing, documenting and provide Vitamin K2
menaquinone-7 . Its brand MenaQ7® is supported by a global IPR portfolio and
research substantiating clear positive clinical efficacy for bone and
cardiovascular health. NattoPharma has since 2007 been in a research and
development collaboration with VitaK, University in Maastricht, The Netherlands,
working to substantiate the health benefits of natural vitamin K2.

For more information, please contact:

Hogne Vik,

CEO (+47-97535326

Hogne.vik@nattopharma.com

or

Kate Quackenbush

Director of Communications

(609) 643-0748

kate.quackenbush@nattopharma.com